A consistent body of evidence supports an independent association between uric acid (UA) level and the risk of chronic kidney disease (CKD) in humans. It has been observed in experimental data that UA is capable of inducing renal damage through several pathways, including activation of the renin-angiotensinaldosterone system (RAAS), oxidative stress, and inflammation. Treatment with urate lowering agents and RAAS inhibitors prevented renal insult mediated by UA in animal models. Both of the xanthine oxidase inhibitors available in clinical practice, allopurinol and febuxostat, were efficient in controlling gout flares. However, data from randomised controlled trials are still inconsistent in relation to their benefit for slowing CKD progression. This review discusses the metabolism of urates in humans as well as the experimental and clinical evidence linking UA to CKD. Current evidence about the effect of allopurinol and febuxostat on CKD progression is also considered.

Uric Acid in chronic kidney disease : a clinical appraisal / A. Galassi, M.E. Giovenzana, F. Prolo, A. Bellasi, M. Cozzolino. - In: EUROPEAN MEDICAL JOURNAL. NEPHROLOGY. - ISSN 2053-4248. - 4:1(2016 Jul), pp. 78-83.

Uric Acid in chronic kidney disease : a clinical appraisal

A. Bellasi
Penultimo
;
M. Cozzolino
Ultimo
2016-07

Abstract

A consistent body of evidence supports an independent association between uric acid (UA) level and the risk of chronic kidney disease (CKD) in humans. It has been observed in experimental data that UA is capable of inducing renal damage through several pathways, including activation of the renin-angiotensinaldosterone system (RAAS), oxidative stress, and inflammation. Treatment with urate lowering agents and RAAS inhibitors prevented renal insult mediated by UA in animal models. Both of the xanthine oxidase inhibitors available in clinical practice, allopurinol and febuxostat, were efficient in controlling gout flares. However, data from randomised controlled trials are still inconsistent in relation to their benefit for slowing CKD progression. This review discusses the metabolism of urates in humans as well as the experimental and clinical evidence linking UA to CKD. Current evidence about the effect of allopurinol and febuxostat on CKD progression is also considered.
Uric Acid (UA); Chronic Kidney Disease (CKD); allopurinol; febuxostat; humans
Settore MED/14 - Nefrologia
11-apr-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Galassi Uric Acid EMJ Nephrol 2016.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 102.94 kB
Formato Adobe PDF
102.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/415417
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact